SEC Form 4 · accession 0001225208-18-003964
PFIZER INC · PFE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Albert Bourla
Officer — Chief Operating Officer · Director
Period of report
Feb 22, 2018
Accepted (ET)
Feb 23, 2018 · 3:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000078003
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Appreciation RightsF1 | $35.74 | Feb 22, 2018 | A | 270,910 | A | Feb 22, 2023 | Feb 22, 2023 | Common Stock | 270,910 | 270,910 | D |
| Stock Appreciation RightsF2 | $35.74 | Feb 22, 2018 | A | 226,485 | A | Feb 22, 2025 | Feb 22, 2025 | Common Stock | 226,485 | 226,485 | D |
Explanation of responses
- F1The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.
- F2The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.